Document Detail


Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.
MedLine Citation:
PMID:  18535024     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To study the effect of combination therapy with aspirin and dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient ischaemic attack (TIA) or minor stroke of presumed arterial origin and to perform subgroup analyses to identify patients that might benefit most from secondary prevention with A+D. DATA SOURCES: The previously published meta-analysis of individual patient data was updated with data from ESPRIT (n = 2,739); trials without data on the comparison of A+D versus ASA were excluded. Review METHODS: A meta-analysis was performed using Cox regression, including several subgroup analyses and following baseline risk stratification. RESULTS: A total of 7612 patients (five trials) were included in the analyses, 3800 allocated to A+D and 3812 to ASA alone. The trial-adjusted hazard ratio (HR) for the composite event of vascular death, non-fatal myocardial infarction and non-fatal stroke was 0.82 (95% confidence interval (CI) 0.72 to 0.92). HRs did not differ in subgroup analyses based on age, sex, qualifying event, hypertension, diabetes, previous stroke, ischaemic heart disease, aspirin dose, type of vessel disease and dipyridamole formulation, nor across baseline risk strata as assessed with two different risk scores. A+D were also more effective than ASA alone in preventing recurrent stroke; HR 0.78 (95% CI 0.68 to 0.90). CONCLUSION: The combination of aspirin and dipyridamole is more effective than aspirin alone in patients with TIA or ischaemic stroke of presumed arterial origin in the secondary prevention of stroke and other vascular events. This superiority was found in all subgroups and was independent of baseline risk.
Authors:
P H A Halkes; L J Gray; P M W Bath; H-C Diener; B Guiraud-Chaumeil; F M Yatsu; A Algra
Related Documents :
10356104 - Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: ...
11680444 - A clinical trial of estrogen-replacement therapy after ischemic stroke.
20864944 - Prehypertension, racial prevalence and its association with risk factors: analysis of t...
7778964 - Determinants of black-white differences in the risk of cerebral infarction. the nationa...
22333874 - Low-carbohydrate, high-protein score and mortality in a northern swedish population-bas...
21463214 - Perception and attitude of women with previous caesarean section towards repeat caesare...
Publication Detail:
Type:  Journal Article; Meta-Analysis     Date:  2008-06-05
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  79     ISSN:  1468-330X     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-22     Completed Date:  2008-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1218-23     Citation Subset:  IM    
Affiliation:
Department of Neurology, Rudolf Magnus Institute of Neuroscience and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Aspirin / therapeutic use*
Dipyridamole / therapeutic use*
Drug Therapy, Combination
Humans
Ischemic Attack, Transient / prevention & control*
Platelet Aggregation Inhibitors / therapeutic use*
Risk Factors
Stroke / prevention & control*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 58-32-2/Dipyridamole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis.
Next Document:  Relapses in multiple sclerosis are age- and time-dependent.